CRNX
Income statement / Annual
Last year (2023), Crinetics Pharmaceuticals, Inc.'s total revenue was $4.01 M,
a decrease of 15.28% from the previous year.
In 2023, Crinetics Pharmaceuticals, Inc.'s net income was -$214.53 M.
See Crinetics Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$4.01 M
|
$4.74 M
|
$1.08 M
|
$71,000.00
|
$1.19 M
|
$2.43 M
|
$2.05 M
|
$589,000.00
|
| Cost of Revenue |
$0.00 |
$1.39 M |
$1.26 M |
$57.00 M |
$1.11 M |
$24.48 M |
$9.23 M |
$5.10 M |
| Gross Profit |
$4.01 M |
$3.35 M |
-$184,000.00 |
-$56.93 M |
$80,000.00 |
-$22.05 M |
-$7.19 M |
-$4.51 M |
| Gross Profit Ratio |
1 |
0.71 |
-0.17 |
-801.79 |
0.07 |
-9.08 |
-3.51 |
-7.66 |
| Research and Development
Expenses |
$168.53 M
|
$130.23 M
|
$84.26 M
|
$57.00 M
|
$41.51 M
|
$24.48 M
|
$9.23 M
|
$5.10 M
|
| General & Administrative
Expenses |
$58.09 M
|
$42.39 M
|
$24.53 M
|
$18.03 M
|
$13.52 M
|
$6.66 M
|
$1.94 M
|
$1.53 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$58.09 M
|
$42.39 M
|
$24.53 M
|
$18.03 M
|
$13.52 M
|
$6.66 M
|
$1.94 M
|
$1.53 M
|
| Other Expenses |
$0.00 |
$4.97 M |
$61,000.00 |
-$71,000.00 |
-$1.19 M |
$1.60 M |
-$48,000.00 |
-$1,000.00 |
| Operating Expenses |
$226.62 M |
$172.62 M |
$108.78 M |
$74.95 M |
$53.83 M |
$28.71 M |
$9.13 M |
$6.04 M |
| Cost And Expenses |
$226.62 M |
$172.62 M |
$108.78 M |
$74.95 M |
$53.83 M |
$28.71 M |
$9.13 M |
$6.04 M |
| Interest Income |
$13.44 M |
$4.32 M |
$157,000.00 |
$991,000.00 |
$3.46 M |
$1.75 M |
$26,000.00 |
$37,000.00 |
| Interest Expense |
$0.00 |
$4.32 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$8,000.00 |
$11,000.00 |
| Depreciation &
Amortization |
$1.10 M
|
$1.39 M
|
$1.26 M
|
$1.23 M
|
$1.11 M
|
$471,000.00
|
$128,000.00
|
$92,000.00
|
| EBITDA |
-$221.51 M
|
-$166.90 M
|
-$106.78 M
|
-$72.59 M
|
-$49.31 M
|
-$28.24 M
|
-$9.00 M
|
-$5.95 M
|
| EBITDA Ratio |
-55.2 |
-35.44 |
-99.91 |
-1055.68 |
-45.12 |
-11.82 |
-4.41 |
-10.04 |
| Operating Income Ratio
|
-55.47
|
-35.44
|
-99.91
|
-1055.68
|
-45.12
|
-11.82
|
-4.46
|
-10.26
|
| Total Other
Income/Expenses Net |
$8.08 M
|
$3.96 M
|
$61,000.00
|
$1.14 M
|
$3.41 M
|
$1.60 M
|
-$30,000.00
|
$25,000.00
|
| Income Before Tax |
-$214.53 M |
-$163.92 M |
-$107.64 M |
-$73.81 M |
-$50.42 M |
-$27.12 M |
-$9.16 M |
-$6.02 M |
| Income Before Tax Ratio
|
-53.46
|
-34.6
|
-99.85
|
-1039.61
|
-42.26
|
-11.17
|
-4.48
|
-10.22
|
| Income Tax Expense |
$0.00 |
-$3.96 M |
-$922,000.00 |
-$948,000.00 |
-$887,000.00 |
$1.60 M |
-$40,000.00 |
$10,000.00 |
| Net Income |
-$214.53 M |
-$159.95 M |
-$106.72 M |
-$72.86 M |
-$49.54 M |
-$27.12 M |
-$9.16 M |
-$6.02 M |
| Net Income Ratio |
-53.46 |
-33.77 |
-99 |
-1026.25 |
-41.52 |
-11.17 |
-4.48 |
-10.22 |
| EPS |
-3.69 |
-3.08 |
-2.78 |
-2.39 |
-2.05 |
-2.23 |
-0.66 |
-0.43 |
| EPS Diluted |
-3.69 |
-3.08 |
-2.78 |
-2.39 |
-2.05 |
-2.23 |
-0.66 |
-0.43 |
| Weighted Average Shares
Out |
$58.07 M
|
$51.98 M
|
$38.44 M
|
$30.45 M
|
$24.18 M
|
$12.14 M
|
$13.88 M
|
$13.88 M
|
| Weighted Average Shares
Out Diluted |
$58.07 M
|
$51.98 M
|
$38.44 M
|
$30.45 M
|
$24.18 M
|
$12.14 M
|
$13.88 M
|
$13.88 M
|
| Link |
|
|
|
|
|
|
|
|
